Compare MLTX & GSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLTX | GSBD |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | N/A |
| Metric | MLTX | GSBD |
|---|---|---|
| Price | $15.69 | $9.26 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 9 | 1 |
| Target Price | ★ $22.22 | $9.00 |
| AVG Volume (30 Days) | ★ 2.3M | 1.5M |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 13.91% |
| EPS Growth | N/A | ★ 69.72 |
| EPS | N/A | ★ 1.14 |
| Revenue | N/A | ★ $383,307,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.06 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.95 | $8.92 |
| 52 Week High | $62.75 | $13.45 |
| Indicator | MLTX | GSBD |
|---|---|---|
| Relative Strength Index (RSI) | 51.98 | 44.84 |
| Support Level | $14.47 | $9.08 |
| Resistance Level | $16.69 | $9.40 |
| Average True Range (ATR) | 0.88 | 0.18 |
| MACD | -0.17 | 0.00 |
| Stochastic Oscillator | 49.79 | 36.40 |
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests primarily in U.S. middle-market companies such as banks and the public debt markets. The company focuses on the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.